ライフサイエンスコーパス: ischaemic

1 6.9%, respectively) compared to those in the ischaemic (63.2 and 3%), sildenafil (41.7 and 28.1%) and

2 f platelet function) with risk of developing ischaemic (AIS), cardioembolic (CES), large artery (LAS)

3 autoimmune, inflammatory, neurodegenerative, ischaemic and acute conditions, such as sepsis, are emer

4 modelling neural insults, including hypoxic-ischaemic and Ca(2+)-dependent injury.

5 here are limited data on predictors of early ischaemic and haemorrhagic complications after AF-associ

6 Predictors of long-term ischaemic and haemorrhagic complications in atrial fibri

7 approaches we investigated associations with ischaemic and haemorrhagic manifestations of small vesse

8 nd oxidation can be lipotoxic and induce non-ischaemic and non-hypertensive cardiomyopathy, termed di

9 enosis, 14 (14.9%) had recurrent strokes (12 ischaemic and two haemorrhagic) during a median follow-u

10 distribution of penumbra and core within the ischaemic area received from different perfusion mapping

11 sed using various programs to obtain defined ischaemic areas and parameters.

12 c' dependencies between collaterally damaged ischaemic areas.

13 patients with ischaemic stroke or transient ischaemic attack (TIA) and AF treated with OAC.

14 ticipants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset.

15 here are few data in patients with transient ischaemic attack (TIA)/stroke.

16 The risk of transient ischaemic attack also seems to be increased in people wi

17 atients, irrespective of age, with transient ischaemic attack and minor ischaemic stroke occurring be

18 dominantly Caucasian patients with transient ischaemic attack and minor ischaemic stroke.

19 tion-based cohort of patients with transient ischaemic attack and minor stroke on intensive medical m

20 risk is substantially lower after transient ischaemic attack and minor stroke.

21 ors for, dementia before and after transient ischaemic attack and stroke.

22 ts with recent ischaemic stroke or transient ischaemic attack in whom the rate of future intracranial

23 A transient ischaemic attack occurred in the high-dose indometacin g

24 sk of dementia, particularly after transient ischaemic attack or minor stroke, are scarce.

25 Patients with transient ischaemic attack or stroke occurring between April 1, 20

26 ementia in patients who have had a transient ischaemic attack or stroke varies substantially dependin

27 s can identify ischaemic stroke or transient ischaemic attack patients at higher absolute risk of int

28 of patients in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and

29 ischaemic event (either stroke or transient ischaemic attack) or a further ICH following study entry

30 ts with recent ischaemic stroke or transient ischaemic attack, cerebral microbleeds are associated wi

31 nya dual infection had a stroke or transient ischaemic attack, compared with five (6%) of 96 patients

32 had a previous history of stroke, transient ischaemic attack, or ischaemic heart disease at baseline

33 ts with recent ischaemic stroke or transient ischaemic attack.

34 roke (ie, NIHSS >10) and lowest in transient ischaemic attack.

35 , and 5.2% (3.4-7.0) in those with transient ischaemic attack.

36 ticipants with ischaemic stroke or transient ischaemic attack; included at least 50 participants; col

37 .4 years [SD 13.0]), 688 (30%) had transient ischaemic attacks and 1617 (70%) had strokes.

38 okes, and 2 years in those who had transient ischaemic attacks.

39 nteraction=0.007), and exerted a significant ischaemic benefit only in this latter group.

40 rs cardiovascular protection from subsequent ischaemic bouts.

41 ffects of hUCBCs in a mouse model of hypoxic-ischaemic brain injury (HI).

42 hock can occur due to acute ischaemic or non-ischaemic cardiac events, or from progression of long-st

43 The survival of ischaemic cardiomyocytes after myocardial infarction (MI

44 aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced left ventricular ej

45 arily treated patients with ischaemic or non-ischaemic cardiomyopathy.

46 syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events.

47 d group displayed improvement in most of the ischaemic changes.

48 ells and thus contributes to the anaemic and ischaemic complications of SCA.

49 We investigated whether remote ischaemic conditioning could reduce the incidence of car

50 Remote ischaemic conditioning does not improve clinical outcome

51 e control group and 239 (9.4%) in the remote ischaemic conditioning group (hazard ratio 1.10 [95% CI

52 her the control group (n=2701) or the remote ischaemic conditioning group (n=2700).

53 treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or

54 ing intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia

55 ted adverse events or side effects of remote ischaemic conditioning were observed.

56 Remote ischaemic conditioning with transient ischaemia and repe

57 with ischaemic stroke were more likely than ischaemic controls to occur in Asians (18.8% vs 6.7%, p<

58 The association of ischaemic core and penumbral volumes with 90-day mRS sco

59 imaging assessments of irreversibly injured ischaemic core and potentially salvageable penumbra volu

60 who had diffusion MRI, after adjustment for ischaemic core volume (odds ratio [OR] 0.47 [95% CI 0.30

61 Increasing ischaemic core volume was associated with reduced likeli

62 Estimated ischaemic core volume was independently associated with

63 Combining ischaemic core volume with age and expected imaging-to-r

64 n 50% endovascular reperfusion (n=186), age, ischaemic core volume, and imaging-to-reperfusion time w

65 critically hypoperfused tissue volume minus ischaemic core volume.

66 Ischaemic core was estimated, before treatment with eith

67 gh glucose itself becomes protective against ischaemic damage.

68 knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an im

69 ow-up, or further adjusting for small-vessel ischaemic disease volumes.

70 Hypoxic-ischaemic encephalopathy (HIE) affects 2-4/1000 live ter

71 Neonatal hypoxic-ischaemic encephalopathy (HIE) is a leading cause of dea

72 nical ventilation and risk of death, hypoxic ischaemic encephalopathy or respiratory arrest did not v

73 es of interest were occurrence of a cerebral ischaemic event (either stroke or transient ischaemic at

74 The coprimary outcomes were recurrent ischaemic event (stroke/TIA/systemic arterial embolism)

75 There were 70 cerebral ischaemic events (AER 2.93 per 100 patient-years); 29 in

76 to determine independent predictors of early ischaemic events (stroke/TIA/systemic embolism) and d-sI

77 qualified; 104 patients (6.8%) had recurrent ischaemic events and 23 patients (1.5%) had d-sICH withi

78 e the cornerstone of secondary prevention of ischaemic events but substantially increase the risk of

79 rdiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy.

80 actors associated with a trend for recurrent ischaemic events were prior stroke or transient ischemic

81 with previous stenting, are at high risk of ischaemic events.

82 ocation did not influence risk of subsequent ischaemic events.

83 d-sICH are different than those of recurrent ischaemic events; therefore, recognising these predictor

84 epidermal thickness showed a decrease in the ischaemic group (23.1 mum) that was significantly increa

85 Histologically, the ischaemic group exhibited dermal disorganization and inf

86 The ischaemic group were administered local nicotine injecti

87 in addition to the same intervention as the ischaemic group.

88 ronic focal and multifocal brain injuries of ischaemic, haemorrhagic and traumatic aetiology.

89 ase subtypes, we observed a 9% lower risk of ischaemic heart disease (0.91, 0.85-0.98), a non-signifi

90 erebrovascular disease (1.09, 1.04-1.14) and ischaemic heart disease (1.10, 1.09-1.11); and low birth

91 The biggest contributors were ischaemic heart disease (152 171 excess deaths), respira

92 d metabolism (OR 1.22, 95% CI 1.12-1.34) and ischaemic heart disease (OR 1.30, 95% CI 1.15-1.47).

93 for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to com

94 cer, one patient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis,

95 sion, cardiac remodelling, and the resulting ischaemic heart disease and heart failure.

96 d children with Kawasaki disease, leading to ischaemic heart disease and myocardial infarction.

97 e CKB, 489 586 participants without previous ischaemic heart disease and stroke at recruitment were i

98 and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

99 ry of stroke, transient ischaemic attack, or ischaemic heart disease at baseline.

100 Ischaemic heart disease evokes a complex immune response

101 oke and increased by 4.6% (-3.3 to 10.7) for ischaemic heart disease from 1990 to 2017.

102 Ischaemic heart disease has a multifactorial aetiology a

103 quality of medical education with a focus on ischaemic heart disease prevention for physicians, nurse

104 osclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health bu

105 in the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

106 in the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

107 s of the prospective population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

108 DALY rates for ischaemic heart disease were greater in urban areas.

109 Comorbidities such as ischaemic heart disease were obtained from their medical

110 Stroke and ischaemic heart disease were the leading causes of death

111 al admissions (74 313 for stroke, 69 446 for ischaemic heart disease) between 2009 and 2016.

112 Given that many factors contribute to ischaemic heart disease, a multifactorial approach to pr

113 level 3 causes were lower than expected for ischaemic heart disease, Alzheimer's disease, headache d

114 reased annually by 3.6% for stroke, 5.4% for ischaemic heart disease, and 4.2% for any cause, between

115 y rates, and mean length of stay for stroke, ischaemic heart disease, and any cause in all relevant i

116 decreased by around 2% annually for stroke, ischaemic heart disease, and any cause, but decreased to

117 ad higher case fatality rates for stroke and ischaemic heart disease, but greater reductions in case

118 ular events outcome that also included other ischaemic heart disease, coronary revascularisation, and

119 for atherosclerotic cardiovascular disease, ischaemic heart disease, ischaemic stroke, or peripheral

120 Age-standardised stroke, ischaemic heart disease, lung cancer, chronic obstructiv

121 patients with multivessel disease and stable ischaemic heart disease, non-ST-segment elevation acute

122 t DALYs were mostly those causing mortality (ischaemic heart disease, perinatal conditions, chronic r

123 an lower socioeconomic groups for stroke and ischaemic heart disease.

124 ctions in case fatality rates for stroke and ischaemic heart disease.

125 role for lipoprotein(a) and triglycerides in ischaemic heart disease.

126 tein(a), and triglycerides for prevention of ischaemic heart disease.

127 n the prevention, diagnosis and treatment of ischaemic heart disease.

128 nd confocal Ca(2+) imaging in a rat model of ischaemic HF.

129 standard care for term infants with hypoxic-ischaemic (HI) encephalopathy.

130 pha5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex.

131 gen and cellular metabolism is a hallmark of ischaemic injury in acute stroke.

132 omeningeal vessels and may trigger secondary ischaemic injury in affected areas.

133 fast UF(NET) rates are also associated with ischaemic injury to the heart, brain, kidney and gut.

134 ent in cardiac function in models of cardiac ischaemic injury(4,5).

135 aemic lesions, severe hypoattenuation, large ischaemic lesion, swelling and hyperattenuated arteries

136 ting changes (atrophy, leucoaraiosis and old ischaemic lesions).

137 Visible ischaemic lesions, severe hypoattenuation, large ischaem

138 s with pain management related to a severely ischaemic limb.

139 d immediately after delayed tPA treatment in ischaemic mice, haemorrhagic transformation was signific

140 agent that improves energy metabolism of the ischaemic myocardium and might improve outcomes and symp

141 pha gene increases the risk of non-arteritic ischaemic optic neuropathy (NAION) and the second eye in

142 s with new or recurrent clinically diagnosed ischaemic or haemorrhagic (excluding subarachnoid haemor

143 Cardiogenic shock can occur due to acute ischaemic or non-ischaemic cardiac events, or from progr

144 Patients aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced le

145 ICDs in contemporarily treated patients with ischaemic or non-ischaemic cardiomyopathy.

146 ion, has been implicated in diseases such as ischaemic organ damage and cancer(1,2).

147 mber of ventricular ectopic beats during the ischaemic phase compared with acute treatment (10 +/- 3

148 ents having a sham procedure, but not remote ischaemic preconditioning (AKI OR 1.35, 0.76-2.39 and pe

149 Remote ischaemic preconditioning (RIPC), induced by brief bouts

150 Remote ischaemic preconditioning (RIPC), induced by intermitten

151 evious work shows that high glucose prevents ischaemic preconditioning and causes electrical and mech

152 rt) and who were randomly assigned to remote ischaemic preconditioning or a sham procedure.

153 und that the loss of BBB integrity following ischaemic/reperfusion-like conditions was significantly

154 ve tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk.

155 ed assessors coded baseline images for acute ischaemic signs (presence, extent, swelling and attenuat

156 es could be considered for the prevention of ischaemic small vessel disease but the net benefit of su

157 ial role is the limited capabilities of cold ischaemic storage.

158 85-0.98), a non-significant 9% lower risk of ischaemic stroke (0.91, 0.82-1.01), and a 32% lower risk

159 k 1.58, 95% CI 1.36-1.84, p<0.0001) than for ischaemic stroke (1.27, 1.13-1.43, p=0.0001).

160 -HAs) on brain MRI and prognosis after acute ischaemic stroke (AIS).

161 morrhage but this effect was less marked for ischaemic stroke (for five or more cerebral microbleeds,

162 ds in mortality and functional dependence by ischaemic stroke (IS) aetiological subtype over a 16-yea

163 a-scoring approach, we develop a metaGRS for ischaemic stroke (IS) and analyse this score in the UK B

164 clinical outcomes in patients with previous ischaemic stroke (IS) or ICH.

165 U-shaped associations with the incidence of ischaemic stroke (n=14 930), intracerebral haemorrhage (

166 We included patients with acute ischaemic stroke (National Institutes of Health Stroke S

167 nt services with a lacunar or minor cortical ischaemic stroke (National Institutes of Health Stroke S

168 Intracerebral haemorrhage and small vessel ischaemic stroke (SVS) are the most acute manifestations

169 ]) and mortality at 5 years was 17% ([17-18] ischaemic stroke 16% [15-16], intracerebral haemorrhage

170 41% (41-42) had recurrent stroke at 5 years (ischaemic stroke 41% [41-42], intracerebral haemorrhage

171 stimulation is safe for patients with acute ischaemic stroke 8-24 h after onset, who are ineligible

172 A similar inverse association was found for ischaemic stroke [prevalent CAD (OR 0.78; 95% CI 0.67, 0

173 unctional MRI data of 31 patients with acute ischaemic stroke and 17 age-matched healthy control subj

174 In patients with ischaemic stroke and AF, predictors of d-sICH are differ

175 mostly observational data from patients with ischaemic stroke and atrial fibrillation treated with he

176 e extension of leukoaraiosis and severity of ischaemic stroke and brain atrophy.

177 ain barrier, namely malignant brain tumours, ischaemic stroke and haemorrhagic traumatic contusion.

178 Stroke, including acute ischaemic stroke and intracerebral haemorrhage, results

179 s and brain imaging to differentiate between ischaemic stroke and intracerebral haemorrhage.

180 en a wide range of haematological traits and ischaemic stroke and its subtypes.

181 trointestinal bleeding), patients with acute ischaemic stroke and patients with an intracardiac throm

182 ligible patients (age >=18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg o

183 to initiate DOAC administration after recent ischaemic stroke and whether the timing should differ ac

184 eriods, so the long-term outcomes post-minor ischaemic stroke are unclear.

185 to later oral anticoagulation with DOACs in ischaemic stroke associated with atrial fibrillation are

186 were aged 18 years or older with a disabling ischaemic stroke at the time of randomisation, had been

187 Ischaemic stroke at young age is an increasing problem i

188 Ischaemic stroke caused by arterial occlusion is respons

189 anial stenosis conveyed an increased risk of ischaemic stroke compared with no intracranial stenosis

190 Acute ischaemic stroke disturbs healthy brain organization, pr

191 t countries, we enrolled patients with acute ischaemic stroke due to large vessel occlusion within a

192 rt oral anticoagulant (OAC) in patients with ischaemic stroke due to non-valvular atrial fibrillation

193 atomical distribution or burden, the rate of ischaemic stroke exceeded that of intracranial haemorrha

194 icipants were patients presenting with acute ischaemic stroke from anterior circulation large-vessel

195 Management of ischaemic stroke has greatly advanced, with rapid reperf

196 n, patients with high-risk non-cardioembolic ischaemic stroke identified on MRI were randomly assigne

197 tine ganglion stimulation 8-24 h after acute ischaemic stroke improved functional outcome.

198 5% CI 1.04-1.96), the risk of same-territory ischaemic stroke in patients with 70-99% symptomatic int

199 to commence DOAC administration after acute ischaemic stroke in patients with atrial fibrillation.

200 ature through a PubMed search, we found that ischaemic stroke in people with migraine is strongly ass

201 t increased risk of myocardial infarction or ischaemic stroke in the absence of established cardiovas

202 t pooled data from consecutive patients with ischaemic stroke in the setting of AF from stroke regist

203 Patients aged 18-85 years with acute ischaemic stroke involving cerebral cortex (National Ins

204 Although the risk of early recurrent ischaemic stroke is high in this population, early oral

205 r ischaemic stroke, but the absolute risk of ischaemic stroke is higher than that of intracranial hae

206 gy, HIF stabilisation and neuroprotection in ischaemic stroke merits further investigation.

207 In summary, acute ischaemic stroke not only prompted changes in connectivi

208 e, with transient ischaemic attack and minor ischaemic stroke occurring between March 1, 2011, and Ma

209 = 603); and (ii) patients with recent minor ischaemic stroke of the Mild Stroke Study (n = 155).

210 eart attack and angina) or stroke (including ischaemic stroke or haemorrhagic stroke).

211 me was the composite outcome of TIA, stroke (ischaemic stroke or intracranial haemorrhage) or death w

212 In adjusted analyses, early OAC after acute ischaemic stroke or TIA associated with AF was not assoc

213 inception cohort study of 1490 patients with ischaemic stroke or transient ischaemic attack (TIA) and

214 ed-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) wit

215 al microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom t

216 atterns of cerebral microbleeds can identify ischaemic stroke or transient ischaemic attack patients

217 In patients with recent ischaemic stroke or transient ischaemic attack, cerebral

218 ta from cohort studies in adults with recent ischaemic stroke or transient ischaemic attack.

219 spectively recruited adult participants with ischaemic stroke or transient ischaemic attack; included

220 trials included patients who had experienced ischaemic stroke recently (within the first few weeks).

221 Ischaemic stroke recurred in 29 (3%) of 932 patients (an

222 in or clopidogrel had a reduced incidence of ischaemic stroke recurrence and a similar risk of severe

223 issue atrophy of extent of leukoaraiosis and ischaemic stroke severity.

224 Secondary prevention of ischaemic stroke shares many common elements with cardio

225 matological traits contribute equally to all ischaemic stroke subtypes is uncertain.

226 ospective, population-based cohort of 1-year ischaemic stroke survivors (Oxford Vascular Study; 2002-

227 st and prolonged systemic immune response to ischaemic stroke that occurs in three phases: an acute p

228 d angiography allows a positive diagnosis of ischaemic stroke versus mimics and can identify a large

229 patients treated with alteplase after acute ischaemic stroke was feasible and most likely safe, but

230 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive gr

231 Cases with ischaemic stroke were more likely than ischaemic control

232 rrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs.

233 We identified 578 patients with acute ischaemic stroke who received thrombectomy, 19 had sICH

234 ompare the clinical outcome of patients with ischaemic stroke with anterior large vessel occlusion tr

235 Non-GA during MT for anterior acute ischaemic stroke with current-generation stent retriever

236 nd patient is a 62-year-old woman who had an ischaemic stroke with massive haemorrhagic conversion re

237 tion, coronary revascularization or presumed ischaemic stroke) and the interaction with ADCY9 rs19673

238 ic intracerebral haemorrhage) and secondary (ischaemic stroke) outcomes for up to 5 years (reported e

239 28-day mortality was 3% (95% CI 3-4) for ischaemic stroke, 47% (46-48)for intracerebral haemorrha

240 8 (80%) of the incident cases of stroke were ischaemic stroke, 7440 (16%) were intracerebral haemorrh

241 After a first ischaemic stroke, 91% of recurrent strokes were also isc

242 infarct size, in preclinical models of acute ischaemic stroke, and showed potential benefit in a pilo

243 improved clinical outcome in patients after ischaemic stroke, and thus S44819 cannot be recommended

244 t association of rs2293871 with small vessel ischaemic stroke, and two blood expression quantitative

245 subsequent intracranial haemorrhage than for ischaemic stroke, but the absolute risk of ischaemic str

246 intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure

247 monitoring cardiovascular disease (including ischaemic stroke, intracerebral haemorrhage, and myocard

248 ring the study period were recorded by type (ischaemic stroke, intracerebral haemorrhage, subarachnoi

249 ke occurs in about one in four patients with ischaemic stroke, more commonly in lacunar strokes.

250 40-85 years) with anterior-circulation acute ischaemic stroke, not undergoing reperfusion therapy.

251 vents (myocardial infarction, heart failure, ischaemic stroke, or death) with the landmark set at 1 y

252 iovascular disease, ischaemic heart disease, ischaemic stroke, or peripheral arterial disease.

253 al myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospital

254 herapy in patients with anterior circulation ischaemic stroke, published in PubMed from Jan 1, 2010,

255 ional and novel risk factors for early-onset ischaemic stroke, such as air pollution.

256 any symptomatic intracranial haemorrhage or ischaemic stroke, symptomatic intracranial haemorrhage,

257 able new targets for secondary prevention of ischaemic stroke, while factor VIII and gamma' fibrinoge

258 ry prevention of atrial fibrillation-related ischaemic stroke, with around half the risk of intracran

259 and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therap

260 emorrhage, and 41% of recurrent strokes were ischaemic stroke.

261 rage from a cohort of 18 patients with acute ischaemic stroke.

262 patients treated with alteplase after acute ischaemic stroke.

263 alone in patients at high risk for recurrent ischaemic stroke.

264 independently predicts early mortality after ischaemic stroke.

265 d-to-moderate atrial fibrillation-associated ischaemic stroke.

266 ceiving alteplase for mild-to-moderate acute ischaemic stroke.

267 emorrhagic complications after AF-associated ischaemic stroke.

268 the rate of first recurrence of symptomatic ischaemic stroke.

269 to the severity and imaging features of the ischaemic stroke.

270 ic intracranial haemorrhage, and symptomatic ischaemic stroke.

271 cranial haemorrhage and 1.23 (1.08-1.40) for ischaemic stroke.

272 ted with an increased frequency of recurrent ischaemic stroke.

273 plays a fundamental part in the occurence of ischaemic stroke.

274 solute risk of intracranial haemorrhage than ischaemic stroke.

275 enhancing clinical recovery of patients with ischaemic stroke.

276 icacy of oral S44189 in patients with recent ischaemic stroke.

277 VSIAs, and the most common complication was ischaemic stroke.

278 in K antagonists (VKAs) to prevent recurrent ischaemic stroke.

279 in patients treated with alteplase for acute ischaemic stroke.

280 rence of the coronary heart disease event or ischaemic stroke.

281 ertensive disease, myocardial infarction and ischaemic stroke.

282 ar thrombectomy in patients who had an acute ischaemic stroke.

283 onset, characteristics and outcome of acute ischaemic stroke.

284 upper limb motor deficits 2-13 months after ischaemic stroke.

285 ts with transient ischaemic attack and minor ischaemic stroke.

286 site outcome of intracranial haemorrhage and ischaemic stroke; 2.45 (1.82-3.29) for intracranial haem

287 c stroke, 91% of recurrent strokes were also ischaemic stroke; after an intracerebral haemorrhage, 56

288 acranial haemorrhage vs 1.47 [1.19-1.80] for ischaemic stroke; for ten or more cerebral microbleeds,

289 artial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombot

290 years; and for >=20 cerebral microbleeds, 73 ischaemic strokes [46-108] per 1000 patient-years vs 39

291 ge (for ten or more cerebral microbleeds, 64 ischaemic strokes [95% CI 48-84] per 1000 patient-years

292 They were compared with 1384 strokes (1193 ischaemic strokes and 191 intracerebral haemorrhages) in

293 We collected data on 86 strokes (81 ischaemic strokes and 5 intracerebral haemorrhages) in p

294 About 13-26% of all acute ischaemic strokes are related to non-valvular atrial fib

295 versus 7/358 (2%) in the early-OAC group (5 ischaemic strokes or TIAs and 2 deaths).

296 e-OAC group (2 intracranial haemorrhages, 18 ischaemic strokes or TIAs and 31 deaths (three deaths we

297 deaths (three deaths were as a result of new ischaemic strokes)) versus 7/358 (2%) in the early-OAC g

298 Of the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/=80 years, of w

299 he donor lung of 300 mm Hg or less; expected ischaemic time longer than 6 h; donor age 55 years or ol

300 assessed for their viability in dividing the ischaemic zone into penumbra and core.